http://www.nmcd-journal.com/article/S0939-4753(14)00315-9/abstract?cc=y Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome – A randomised controlled trial M.D. Witham, Dr F. Adams,S. McSwiggan,G. Kennedy,G. Kabir,J.J.F. Belch,F. Khan Medical Research Institute, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, Scotland Received: August 2, 2014; Received in revised form: October 1, 2014; Accepted: October 14, 2014; Published Online: October 22, 2014 Highlights We randomised 50 patients with CFS/ME to receive six months of intermittent high-dose vitamin D or placebo. Vitamin D did not improve pulse-wave velocity or flow-mediated dilatation of the brachial artery compared to placebo. Vitamin D did not improve markers of oxidative stress or inflammation compared to placebo. Vitamin D did not improve symptoms of fatigue compared to placebo. Abstract Background and aims Low 25-hydroxyvitamin D levels are common in patients with chronic fatigue syndrome; such patients also manifest impaired vascular health. We tested whether high-dose intermittent oral vitamin D therapy improved markers of vascular health and fatigue in patients with chronic fatigue syndrome. Methods and Results Parallel-group, double-blind, randomised placebo-controlled trial. Patients with chronic fatigue syndrome according to the Fukuda (1994) and Canadian (2003) criteria were randomised to receive 100,000 units oral vitamin D3 or matching placebo every 2 months for 6 months. The primary outcome was arterial stiffness measured using carotid-femoral pulse wave velocity at 6 months. Secondary outcomes included flow-mediated dilatation of the brachial artery, blood pressure, cholesterol, insulin resistance, markers of inflammation and oxidative stress, and the Piper Fatigue scale. 50 participants were randomised; mean age 49 (SD 13) years, mean baseline pulse wave velocity 7.8 m/s (SD 2.3), mean baseline office blood pressure 128/78 (18/12) mmHg and mean baseline 25-hydroxyvitamin D level 46 (18) nmol/L. 25-hydroxyvitamin D levels increased by 22nmol/L at 6 months in the treatment group relative to placebo. There was no effect of treatment on pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% CI -0.6 to 0.6; p=0.93). No improvement was seen in other vascular and metabolic outcomes, or in the Piper Fatigue scale at 6 months (adjusted treatment effect 0.2 points; 95% CI -0.8 to 1.2; p=0.73). Conclusion High-dose oral vitamin D3 did not improve markers of vascular health or fatigue in patients with chronic fatigue syndrome. Trial registration www.controlled-trials.com, ISRCTN59927814.